Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects With Advanced Solid Tumors
Harbour BioMed (Guangzhou) Co. Ltd
Patients eligible to participate in this trial will receive 3-4 cycles of escalating doses of HBM4003. HBM4003 will be intravenously administered on Days 1, 8, 15 and 22 of a 28 day cycle.